SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Far below the surface, where light no longer reaches and noise collapses into silence, the Sperm Whale endures.  It does not rely on speed or spectacle. It survives through mass, intelligence, and absolute awareness of its surroundings.  This project is shaped by the same principle — strength formed under pressure, movement guided by understanding, and conviction built where others cannot remain.  While the surface reacts, the deep decides.

The Sperm Whale

SPERMWHALE has become a focal point of intense community debate, with users sharply divided between those calling it a speculative meme coin and others highlighting its rapid volatility as a high-risk trading opportunity. While some participants actively promote the asset as a potential high-growth play, critics frequently dismiss it as a pump-and-dump scheme, fueling widespread discussion over the viability of viral, low-market-cap tokens.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

VCX is experiencing significant volatility and trending attention as retail investors speculate on its high-profile private company portfolio, including holdings like SpaceX and OpenAI. The stock is seeing heavy trading activity and community discussion centered on the impact of a six-month lockup period, which has limited available float and fueled intense debate over its valuation relative to its underlying net asset value.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Transocean (RIG) is capturing significant investor attention as it reports earnings and navigates a high-profile merger with Valaris, creating a combined entity with a massive multi-billion dollar backlog. Community sentiment remains polarized, with bullish investors highlighting improved fleet utilization and debt reduction as long-term catalysts, while others debate the impact of the merger dilution and the company's historical volatility.

Arena-Z

Arena-Z is gaining momentum following its recent rebranding from LOKA and a shift toward powering a broader gaming ecosystem. Investors are actively discussing the project's growth potential and calling for community-driven buying pressure to accelerate its market performance.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is trending as investors aggressively position themselves ahead of the company's earnings release, with heavy community speculation focusing on potential updates regarding NASA's Lunar Terrain Vehicle contract. Sentiment remains divided between those betting on transformative revenue growth and a potential short squeeze, and those highlighting the execution risks inherent in the aerospace sector.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals is seeing a surge in investor interest and trading volume driven by persistent market speculation regarding potential M&A activity. While retail sentiment remains highly divided between long-term holders hopeful for a buyout premium and skeptics wary of the lack of official confirmation, the unusual after-hours price action has prompted significant discussion across community forums.

NEOS ETF Trust - NEOS Nasdaq 100 High Income ETF

NEOS Nasdaq 100 High Income ETF

Investors are heavily focused on QQQI for its consistent monthly distributions and tax-efficient return of capital, cementing its status as a core income generator in portfolios. The community continues to debate the trade-offs between capped upside potential in covered call strategies versus the benefit of high yields, with many actively dollar-cost averaging into the dip to lock in long-term passive income.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Berkeley Heights, NJ.

Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals is trending as investors react to a recent insider purchase by CEO Seth Lederman, fueling speculation about upcoming product catalysts and potential institutional interest. Community sentiment remains deeply divided, with bulls pointing to growing prescription data for their fibromyalgia treatment as a path to profitability, while bears continue to express concerns over historical dilution and the company's long-term cash runway.

What Is Tezos (XTZ)?   Tezos is a high-performing blockchain and open-source platform for assets and applications, with a strong focus on code security, on-chain governance, and decentralization. Tezos 2.0, the upcoming step in the evolution of Tezos, aims to improve scalability (via layer 2s), composability, and to implement support to mainstream programming languages (like Javascript, Typescript, Python, and many others).   Initially built with formal verification in mind, the Tezos protocol enables builders to avoid bugs when developing smart contracts, making it particularly suited to applications that require a high degree of security and certainty.   Tezos’ LPoS (Liquid Proof-of-Stake) consensus mechanism enables any stakeholder to take part, directly or by delegation, in the consensus process, and to be rewarded for securing the network. Rather uniquely, Tezos’ on-chain governance system also enables stakeholders to create and vote on protocol upgrade proposals. This pioneering system allows the protocol to self-amend and upgrade itself without leading to a split (or fork) in the blockchain, empowering the community without slowing down innovation.   First proposed in 2014 and launched in 2018, the Tezos Mainnet has a proven track record of running uninterrupted ever since, having earned a strong reputation for technical excellence and a supportive community.    Who Are the Founders of Tezos? Tezos was conceived by Arthur and Kathleen Breitman in a 2014 white paper under the pseudonym L.M. Goodman in a nod to Satoshi Nakamoto, referencing a journalist who had misidentified the creator of Bitcoin.   In a previous paper, the Breitmans had argued that Bitcoin's biggest shortcomings were the lack of a governance process that invited contributions from its community of users, cost and centralization issues raised by its proof-of-work system, the limited expressiveness of its programming language which didn’t allow for smart contracts, and security

Tezos

Tezos is trending as market participants engage in heated debates over its utility and real-world asset integration, with bears aggressively calling for lower prices while bulls maintain focus on long-term staking and recovery potential. The sentiment remains deeply polarized, characterized by high volatility and vocal community disagreement regarding whether the asset represents a viable investment or a speculative trap.

Palladyne AI Corp. engages in the design, development, and manufacture of industrial robotic systems that augment human performance by combining human intelligence, instinct, and judgment with the strength, endurance, and precision of machines to enhance employee safety and productivity. Its products include Palldyne IQ and Palladyne Pilot. The company was founded by Fraser M. Smith and Benjamin G. Wolff in 2015 and is headquartered in Salt Lake City, UT.

Palladyne AI Corp.

Palladyne AI is currently a top trending ticker following a strong Q4 earnings report, updated FY26 revenue guidance, and the announcement of new U.S. Navy and Air Force defense contracts. The community is sharply divided between retail traders betting on a potential short squeeze due to high short interest and long-term investors bullish on the company's strategic pivot into integrated autonomous defense systems.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

RGNX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026

RGNX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026 RGNX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX...

REGENXBIO Inc. $RGNX Shares Bought by JPMorgan Chase & Co.

JPMorgan Chase & Co. increased its holdings in REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 4.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,037,248 shares of the biotechnology company's stock...

OCGN Gene-Agnostic Eye Therapy Could Shift Retinal Drug Development

OCGN's gene-agnostic eye therapy aims to treat multiple retinal mutations, with key filings and pivotal data in 2026???2027 set to test its broad platform.

OCGN Gene Therapy Pipeline: 2026-2027 Catalysts To Watch

Ocugen lines up key gene therapy catalysts through 2027, with pivotal data, filings, and milestones across three eye programs set to drive stock volatility.

Ocugen Stock Outlook: Balancing Cash Burn and Late-Stage Data

Ocugen faces rising cash burn and dilution risk as it advances late-stage gene therapy programs, with 2026-2027 data and filings set to drive volatility.

RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit

RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit PR Newswire NEW YORK, March 19, 2026...

REGENXBIO, Inc. Stockholders Should Contact Robbins LLP for Information About Leading the RGNX Class Action

Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired REGENXBIO, Inc. (NASDAQ: RGNX) securities between February 9, 2022 and...

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines - RGNX

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines - RGNX INVESTOR ALERT: Pomerantz Law Firm Reminds...

STEPHEN PAKOLA OVERSAW RGX-111 SAFETY CLAIMS THAT COST RGNX INVESTORS MILLIONS: SUEWALLST, LLP

STEPHEN PAKOLA OVERSAW RGX-111 SAFETY CLAIMS THAT COST RGNX INVESTORS MILLIONS: SUEWALLST, LLP STEPHEN PAKOLA OVERSAW RGX-111 SAFETY CLAIMS THAT COST RGNX INVESTORS MILLIONS: SUEWALLST, LLP PR...

RGNX SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026

RGNX SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026 RGNX SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP...

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Current Price	$8.34
Prev Close	$8.10
Open	$8.34
Dividend Yield	0.00%
50-Day Moving Average	$10.42
Beta	1.64
Avg. Volume	931,576.48
PE Ratio	-2.22

52-Week High	$16.19
52-Week Low	$5.04
Market Capitalization	$430.45M
EPS (Annual)	-$3.76
Price to Book	4.13
Revenue Per Employee	$459,409.70

RGNX
Regenxbio Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest RGNX News

RGNXRegenxbio Inc